Active — Not RecruitingNot Applicable

Genetic Testing in African Americans

United States21 participantsStarted 2023-04-20

Plain-language summary

This is a pilot/feasibility study to conduct genetic testing using tumor/blood samples of African American and Caucasian patients with ovarian and endometrial cancer following surgery at AU Health Medical Center. The aim of the pilot/feasibility study is to sequence a panel of cancer genes on paired tumor/blood (germline) samples of patients with ovarian and endometrial tumors at a two-week time point following surgery at AU Medical Center. While paired testing of tumor and blood (germline) provides direct clinical value to patients, investigators propose to study whether investigators can define and overcome such minority barriers among the Georgia Cancer Center (GCC)/AU Health Medical Center (AUMC) patient population.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years of age.
✓. New diagnosis of ovarian, endometrial, fallopian, or primary peritoneal carcinoma.
✓. Diagnostic procedure performed at AU Health Medical Center.
✓. Adequate tissue is available for the tumor testing component (e.g., cytology and FNA samples are typically not adequate, whereas core biopsies and open biopsies usually are adequate.
✓. Consent at first post-biopsy outpatient clinic visit (typically about 2 weeks).
✓. Ability to provide informed consent in English.

What they're measuring

Consent rate for germline testing

Timeframe: 12 months

Trial details

NCT IDNCT05591131

SponsorAugusta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-11

View on ClinicalTrials.gov More Ovarian Cancer trials